Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Helix Biopharma Corp (HBPCF)

Helix Biopharma Corp (HBPCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 38,016
  • Shares Outstanding, K 245,108
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,690 K
  • 60-Month Beta 0.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade HBPCF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 06/14/24
  • Next Earnings Date 10/25/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1551 unch
on 08/12/24
0.1551 unch
on 08/12/24
N/A (-6.68%)
since 07/09/24

Most Recent Stories

More News
Proactive news headlines including AEX Gold, Helix BioPharma, Imagine AR, Empower Clinics and Kintara Therapeutics

New York , July 01, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

EXDI : 0.0650 (-10.96%)
SFET : 2.86 (+2.14%)
AVCO : 0.5259 (-16.52%)
GEVO : 1.3500 (-10.00%)
ABML : 9.8300 (unch)
PESI : 11.58 (+1.22%)
KTRA : 0.1817 (+3.83%)
DMPWW : 0.0001 (unch)
HBPCF : 0.7755 (-6.68%)
HBP : 10.70 (+0.19%)
CBDT.CN : 0.050 (unch)
EPWCF : 0.0001 (unch)
Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management

RICHMOND HILL, ON / ACCESSWIRE / June 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment...

HBPCF : 0.7755 (-6.68%)
HBP.TO : 1.29 (+2.38%)
Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants

RICHMOND HILL, ON / ACCESSWIRE / June 24, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment...

HBP.TO : 1.29 (+2.38%)
HBPCF : 0.7755 (-6.68%)
Proactive news headlines including Nextleaf Solutions, KushCo Holdings, INDVR Brands and Aurania Resources

New York , June 15, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

BHSC.CN : 7.6000 (+1.33%)
CNVCF : 5.6000 (+1.40%)
BSGM : 0.3249 (+2.14%)
OILS.CN : 0.0900 (+12.50%)
OILFF : 0.0580 (-2.03%)
KSHB : 0.6950 (+0.14%)
N : 90.34 (unch)
NXTTF : 0.0371 (+3.92%)
RDGMF : 0.1111 (+0.09%)
AREC : 0.6100 (+3.39%)
CODX : 1.2700 (-0.78%)
BIOC : 0.4349 (-13.05%)
Helix Biopharma Corp. Provides Polish Subsidiary Divestiture Update

RICHMOND HILL, ON / ACCESSWIRE / September 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of...

HBPCF : 0.7755 (-6.68%)
HBP.TO : 1.29 (+2.38%)

Business Summary

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Its primary drug candidate is L-DOS47, which is intended for the treatment of inoperable, locally advanced, recurrent, or metastatic non-small cell lung cancer. The Company's product development initiatives...

See More

Key Turning Points

3rd Resistance Point 0.1551
2nd Resistance Point 0.1551
1st Resistance Point 0.1551
Last Price 0.7755
1st Support Level 0.1551
2nd Support Level 0.1551
3rd Support Level 0.1551

See More

Last Price 0.7755
52-Week High 0.1662
Fibonacci 61.8% 0.1620
Fibonacci 50% 0.1606
Fibonacci 38.2% 0.1593
52-Week Low 0.1551

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar